On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children’s Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.

中文翻译：

---

辉瑞-BioNTech COVID-19 疫苗后青少年的心肌周围炎

2021 年 5 月 10 日，辉瑞-BioNTech COVID-19 疫苗 (BNT162b2) 的紧急使用授权扩大到包括青少年（2021 年 5 月 10 日。https://www.fda.gov/news-events/press-announcements /coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use）。我们描述了 8 名青少年的临床特征，他们在接受一剂 BNT162b2 疫苗后 4 天内因心肌周围炎就诊于尼克劳斯儿童医院，为期 36 天。